Jenburkt Pharmaceuticals share price & results
- Jun 2026
- Sept 2026
Jenburkt Pharmaceuticals Limited — a BSE-listed (script code 524731) Indian pharmaceutical company.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 35.5 | −0.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 17.0 | −8.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 5.9 | −24.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 19.42 | +0.8 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 7.86 | +2.4 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 9.07 | +4.1 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −18.2% 1Y
1Y: ₹1,070.2 on 24 Oct 2025 → ₹875.45. High ₹1,275.85 (3 Nov 2025), low ₹870.95 (23 Oct 2026).
- Previous close
- ₹874.55
- Market cap
- ₹388 Cr
- 52-week range
- ₹870.95 – ₹1,275.85
- One year
- −19.62%
- Price to earnings (TTM to Jun 2026)
- 10.86×
- Return on equity (TTM to Jun 2026)
- 19.42%
Overview
- Symbol
- NSE:JENBURPH
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Jenburkt Pharmaceuticals Ltd. does
Based on the company's own presentations, annual report and earnings calls.
Jenburkt Pharmaceuticals Limited is an Indian pharmaceutical company listed on the BSE under script code 524731. The documents available in this bundle are limited to the FY2024-25 AGM notice, e-voting instructions, and shareholder compliance procedures, and do not describe the company's manufacturing operations, plants, product portfolio, or business segments.
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −24% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 41 | 37 | 41 | 36 | 46 | 43 | 45 | 36 |
| Expenses | 30 | 28 | 30 | 27 | 32 | 36 | 30 | 29 |
| Operating profit | 11 | 9 | 11 | 9 | 13 | 7 | 14 | 6 |
| Operating margin | 27.7% | 23.9% | 26.5% | 25.2% | 28.8% | 17.3% | 31.9% | 17.0% |
| Other income | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 13 | 10 | 12 | 10 | 14 | 8 | 14 | 7 |
| Tax rate | 23.3% | 31.6% | 27.9% | 23.5% | 29.1% | 28.6% | 20.9% | 13.0% |
| Net profit | 10 | 7 | 9 | 8 | 10 | 6 | 11 | 6 |
| EPS (₹ per share) | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 137 | 142 | 152 | 169 |
| Expenses | 106 | 109 | 111 | 125 |
| Operating profit | 30 | 33 | 40 | 44 |
| Other income | 5 | 5 | 7 | 6 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 3 | 3 |
| Profit before tax | 33 | 35 | 44 | 47 |
| Net profit | 24 | 26 | 32 | 35 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 5 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 113 | 118 | 141 | 167 | 178 | 193 |
| Borrowings | 7 | 3 | 0 | 4 | 2 | 2 |
| Other liabilities | 18 | 16 | 19 | 19 | 24 | 26 |
| Total liabilities | 143 | 141 | 164 | 195 | 209 | 225 |
| Fixed assets | 11 | 10 | 10 | 15 | 14 | 19 |
| Capital work in progress | 0 | 1 | 1 | 40 | 52 | 46 |
| Investments | 8 | 11 | 17 | 21 | 27 | 27 |
| Other assets | 123 | 119 | 136 | 120 | 116 | 132 |
| Total assets | 143 | 141 | 164 | 195 | 209 | 225 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 19 | 9 | 17 | 8 | 28 | 27 |
| Cash from investing | -19 | -1 | 3 | -1 | -17 | -19 |
| Cash from financing | -1 | -6 | -21 | -7 | -8 | -9 |
| Net cash flow | 0 | 3 | -1 | 0 | 3 | -2 |
| Free cash flow | 18 | 7 | 15 | 6 | 8 | 13 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory days | 92 | 115 | 92 | 103 | 109 | 154 |
| Days payable | 56 | 83 | 67 | 75 | 100 | 91 |
| Cash conversion cycle | 83 | 77 | 70 | 78 | 59 | 115 |
| Working capital days | 17 | 16 | 31 | 36 | 31 | 41 |
| Return on capital employed | 24.0% | 26.0% | 27.0% | 26.0% | 27.0% | 27.0% |
| Dividend payout | 28.0% | 25.0% | 26.0% | 26.0% | 25.0% | 26.0% |
What the price assumes
AttractiveTo justify its price of ₹875, this stock must grow earnings at 2% every year for 7 years. Our analysis caps realistic growth at ~13%. At that growth it is worth ₹1600 — upside of 83%.
- Growth the price implies
- 2.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.5% a year
- net profit, FY23–FY26 · EPS 13.3%
- The gap
- -0.1 pp
- 83% downside if it only repeats history
Ownership
Who owns it
Public hold 53.34% as of Sept 2026; institutions cut 0.09 pts since Jun 2026.
- Promoters 46.62%
- Foreign institutions 0.00%
- Domestic institutions 0.03%
- Public 53.34%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.72% held
- newly disclosed 1.72% held
- newly disclosed 1.72% held
- +0.70 pp 1.72% held
- +0.69 pp 1.72% held
The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Jenburkt Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 18.07% | unchanged | |
| 13.96% | unchanged | |
| 9.06% | unchanged | |
| 2.31% | unchanged | |
| 1.72% | +0.69 pp | |
| 1.72% | +0.70 pp | |
| 1.72% | newly disclosed | |
| 1.72% | newly disclosed | |
| 1.72% | newly disclosed | |
| 1.50% | unchanged | |
| 1.18% | unchanged | |
| 1.17% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Jenburkt Pharmaceuticals Ltd.
Free account: one company. Everything above stays public.
Write why you follow Jenburkt Pharmaceuticals Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- PR
PREVESTPrevest Denpro Limited - IN
INFINIUMInfinium Pharma - AL
ALBERTDAVDAlbert David Limited - HA
HALEOSLABSHALEOS LABS LIMITED - AS
ASARFIASARFI HOSPITAL LIMITED - ME
MEDICAMEQMedicamen Biotech Limited - QM
QMSMEDIQMS Medical Allied Services Limited - AA
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
Learn to analyse Jenburkt Pharmaceuticals Ltd.
Guides on how to read this kind of business and the numbers that matter.